Back to results
US 2023/0416753 A1Published application
Sirna for treating hepatic fibrosis and delivery preparation thereof
AssigneeYoujia (Hangzhou) Biomedical Technology Co., Ltd
InventorsWenhao CUI, Chengjiang ZHAO, Meng WANG, Zhi ZHENG, Huandong TIAN
Life of this patent
Estimating the term…
Abstract
Provided is a siRNA targeting a NOX1 protein for inhibiting the production of reactive oxygen species (ROS) to treat hepatic fibrosis. In addition, the siRNA has an improved effect on the treatment of hepatic fibrosis and non-alcoholic fatty liver.
Claims11
A small interfering RNA that inhibits the expression of target gene NOX1, consisting of a sense strand and an antisense strand reversely complementary thereto, wherein sequences of the sense strand and the antisense strand are selected from the group consisting of:
- (1) sequences of No. 1 small interfering RNA
- the sense strand has a nucleotide sequence of 5′-GAGAUGUGGGAUGAUCGUGACTT-3′ (SEQ ID NO.1), and
- the antisense strand has a nucleotide sequence of 5′-GUCACGAUCAUCCCACAUCUCTT-3′ (SEQ ID NO.2);
- (2) sequences of No. 2 small interfering RNA
- the sense strand has a nucleotide sequence of 5′-CAAGCUGGUGGCCUAUAUGAUTT-3′ (SEQ ID NO.3), and
- the antisense strand has a nucleotide sequence of 5′-AUCAUAUAGGCCACCAGCUUGTT-3′ (SEQ ID NO.4);
- and
- (3) sequences of No. 3 small interfering RNA
- the sense strand has a nucleotide sequence of 5′-CUGAGUCUUGGAAGUGGAUCCUUTT-3′ (SEQ ID NO.5),
- the antisense strand has a nucleotide sequence of 5′-AAGGAUCCACUUCCAAGACUCAGTT-3′ (SEQ ID NO.6);
- wherein, the antisense strand is reversely complementary to a fragment of the target gene.
8 more elements
Dependencies are inferred from the claim text.